Gilead’s Bictegravir-Lenacapavir Tablet Maintains HIV Suppression, Merck CMO Highlights New Drug
Gilead reported that its once-daily single-tablet regimen combining the integrase inhibitor bictegravir with capsid inhibitor lenacapavir maintained virological suppression in HIV-1 patients who switched antiretroviral therapy. Merck’s chief medical officer underscored the potential of its investigational HIV agent for Wall Street but did not disclose trial metrics.
1. Gilead’s Bictegravir-Lenacapavir Regimen Maintains Suppression
Gilead presented data demonstrating that its bictegravir-lenacapavir single-tablet regimen sustained HIV-1 RNA suppression below virological threshold in patients who transitioned from prior antiretroviral therapies. The study evaluated efficacy and tolerability over the initial treatment phase, highlighting Gilead’s strategy in developing long-acting combination therapies.
2. Merck CMO Outlines HIV Drug Potential
Merck’s chief medical officer emphasized the strategic importance of its investigational HIV compound for future market positioning, noting its unique mechanism of action targeting viral replication. While no specific efficacy metrics were released, he signaled that pivotal trial data are expected to follow in upcoming quarters, suggesting a potential competitive threat to established regimens.